NIA‐AA Alzheimer's Disease Framework: Clinical Characterization of Stages is a dataset published in Annals of Neurology (2021). On theSindex it has a DataRank of 2.4, placing it in the top 8.9% of the data-sharing corpus. It has been cited 68 times, with 63 citing works in its 1-hop citation network. Its calibrated FAIR score is 4/100.
Ranks in the top 9% for downstream scientific impact
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Full FAIR picture · advisory
The headline score is computed from the scored criteria — the fact-shaped checks (a repository, an accession, a licence) that two independent models agree on. The advisory criteria below are real FAIR guidance but rest on judgment calls that models read differently, so they inform without moving the number.
The text does not provide a persistent identifier or any URI for the dataset; the only mention is 'available upon request'.
RDA-F1-01D — FAIR Data Maturity Model: 'Data is identified by a persistent identifier' (priorit · RDA-F1-02D — FAIR Data Maturity Model: 'Data is identified by a globally unique identifier' · FsF-F1-02D — F-UJI/FAIRsFAIR: 'Data is assigned a persistent identifier'
No repository is named as the holder of the data; the only statement is 'available upon request'. [majority verdict 'no' (4/5 passes agreed)]
RDA-F4-01M — FAIR Data Maturity Model: metadata is offered so it can be harvested and indexed ( · NIH DMS Policy Element 4 (NOT-OD-21-014) — name the repository where data will be archived · NSTC Desirable Characteristics of Data Repositories (2022) — 'Long-Term Sustainability', 'Reten
No identifier for the dataset appears anywhere in the paper, either in the body or in the reference list.
FORCE11 Joint Declaration of Data Citation Principles (2014) — data should be cited as a first- · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes · FsF-F3-01M — F-UJI: 'Metadata includes the identifier of the data it describes'
Advisory · not in the published score
“Data from the MCSA, including data from this study, are available upon request.”
The statement points to a person (available on request), which is Colavizza category 1. [majority verdict 'partial' (4/5 passes agreed)]
Colavizza, Hrynaszkiewicz, Staden, Whitaker & McGillivray (2020), 'The citation advantage of li · Springer Nature research data policy — Data Availability Statements: standard statement templat · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes
“We evaluated persons without dementia having 3 consecutive clinical visits. Measures for cross‐sectional categories included objective cognitive impairment (OBJ) and function (FXN). Measures for change included subjective cognitive impairment (SCD), objective cognitive change (ΔOBJ), and new onset of neurobehavioral symptoms (ΔNBS).”
The dataset's content is described in running prose in the abstract, but no itemised inventory (section, table, or list of files) is provided. [majority verdict 'partial' (3/5 passes agreed)]
RDA-F2-01M — 'Rich metadata is provided to allow discovery' (priority Essential) · FsF-F2-01M — F-UJI: 'Metadata includes descriptive core elements to support data findability' · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data'
“Data from the MCSA, including data from this study, are available upon request.”
The only route is a discretionary request to a person, which is not a followable access process.
RDA-A1.1-01D — 'Data is accessible through a free access protocol' · FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · NSTC Desirable Characteristics of Data Repositories (2022) — 'Free and Easy Access'
Advisory · not in the published score
“Data from the MCSA, including data from this study, are available upon request.”
The text describes an access action (request) from which the level must be inferred, but no explicit access-level label is given. [majority verdict 'partial' (3/5 passes agreed)]
FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · RDA-A1-01M — metadata contains information to enable the user to get access to the data · COAR Controlled Vocabularies — Access Rights v1.0 (open / embargoed / restricted / metadata-onl
“Data from the MCSA, including data from this study, are available upon request.”
The data are human-subject and the only gatekeeper is the corresponding author, a natural person, with no institutional committee named. [majority verdict 'partial' (4/5 passes agreed)]
NIH Genomic Data Sharing Policy (NOT-OD-14-124) — controlled-access via a Data Access Committee · RDA-A1.2-01D — 'Data is accessible through an access protocol that supports authentication and · NIH DMS Policy Element 5 (NOT-OD-21-014) — Access, Distribution, or Reuse Considerations (conse
No sentence addresses the timing or persistence of the data's availability.
NIH DMS Plan Element 4 (NOT-OD-21-014) — Data Preservation, Access, and Associated Timelines · NSTC Desirable Characteristics (2022), Organizational Infrastructure: 'Retention Policy' · RDA-A2-01M — 'Metadata is guaranteed to remain available after data is no longer available'
No file format of any kind is named for the released data.
FsF-R1.3-02D — F-UJI: 'Data is available in a file format recommended by the target research co · RDA-R1.3-02D — data is expressed in a machine-understandable community standard · RDA-I1-01D — data uses a knowledge representation expressed in a standardised format
Advisory · not in the published score
No named data or metadata community standard from FAIRsharing or EQUATOR is applied to the data.
RDA-R1.3-01M — 'Metadata complies with a community standard' (priority Essential) · RDA-R1.3-01D — 'Data complies with a community standard' · RDA-I2-01M — '(Meta)data use vocabularies that follow FAIR principles'
No identifier (DOI, accession, RRID, or database version) is given for any external resource used; references are to articles only.
RDA-I3-01M — '(meta)data include references to other (meta)data' · RDA-I3-03M — 'metadata includes qualified references to other metadata' · FsF-I3-01M — F-UJI: 'Metadata includes links between the data and its related entities'
No licence or reuse terms are stated for the data; the CC-BY-NC-ND licence applies to the article only.
RDA-R1.1-01M — 'Metadata includes information about the licence under which the data can be reu · RDA-R1.1-02M — 'Metadata refers to a standard reuse licence' · RDA-R1.1-03M — 'Metadata refers to a machine-understandable reuse licence'
No version token or date is given to identify which snapshot of the data was used.
DataCite Metadata Schema 4.6 — the 'Version' property · RDA-R1.2-01M — provenance information (which version was used is provenance) · NSTC Desirable Characteristics of Data Repositories (2022) — 'Provenance', 'Retention Policy'
The paper does not mention any code availability.
NIH DMS Policy Element 2 (NOT-OD-21-014) — 'Related Tools, Software and/or Code' · FAIR4RS Principles v1.0 (Chue Hong et al., 2022; RDA/FORCE11/ReSA) — FAIR Principles for Resear · FORCE11 Software Citation Principles (Smith, Katz & Niemeyer, 2016, PeerJ CS 2:e86)
“Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health (NIH) under Award Numbers U01 AG006786, P30 AG062677, R01 AG011378 and a Zenith Award from the Alzheimer's Association.”
The text provides specific award/grant numbers from a named funder. [majority verdict 'yes' (4/5 passes agreed)]
DataCite Metadata Schema 4.6 — 'FundingReference' property (funderName, funderIdentifier, award · Crossref Funder Registry — canonical funder identifiers for funding metadata · RDA-F2-01M — rich metadata provided to allow discovery (funding is part of the descriptive reco
Advisory · not in the published score
“Amyloid positron emission tomography (PET) imaging was performed with Pittsburgh Compound B.”— not found in the paper; verdict downgraded
The paper names specific instruments and assays used to produce the data. [downgraded to 'partial' — no verifiable quote from the paper] [majority verdict 'partial' (3/5 passes agreed)]
RDA-R1.2-01M — 'Metadata includes provenance information according to community- specific standa · FsF-R1.2-01M — F-UJI: 'Metadata includes provenance information about data creation or generati · W3C PROV-O (W3C Recommendation, 2013) — the entity/activity/agent model of provenance
“TABLE 1. Measurements and Cutoff Points Defining Dimensions Used for NIA‐AA Numeric Clinical Staging”— not found in the paper; verdict downgraded
Variable definitions are provided in a table inside the article, not in a separate documentation file shipped with the data. [downgraded to 'no' — no verifiable quote from the paper] [majority verdict 'no' (3/5 passes agreed)]
RDA-R1-01M — '(Meta)data are richly described with a plurality of accurate and relevant attribu · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data' · NIH DMS Policy Element 3 (NOT-OD-21-014) — Standards (documentation and metadata to accompany t
Calibrated FAIR score — a parallel quality metric, independent of the DataRank citation score. See the full evaluation →
Base Score Contribution
0.635
From this paper's citation signal
Citation Network Contribution
1.8
From 51 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 63 citers.
Alzheimer's Association
Grant: AARG‐17‐531322
Alzheimer's Association
Grant: Zenith Award
National Institutes of Health
Grant: P30 AG062677
National Institutes of Health
Grant: R01 AG011378
National Institutes of Health
Grant: U01 AG006786
NIA NIH HHS
Grant: R01 AG056366
NIA NIH HHS
Grant: R37 AG011378
NIA NIH HHS
Grant: R33 AG058738
National Institutes of Health
Grant: 2U01AG006786-04
ALZHEIMERS DISEASE PATIENT REGISTRY
National Institutes of Health
Grant: 5P30AG062677-02
Mayo Alzheimer's Disease Research Center
National Institutes of Health
Grant: 5R01AG011378-03
MR HIPPOCAMPAL CHANGES IN ALZHEIMERS DISEASE AND AGING
Mayo Foundation for Medical Education and Research
FWCI
6.62
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals